ReviewVaccine2020
Preventing infectious diseases for healthy ageing: The VITAL public-private partnership project.
Review in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Strategies for controlling communicable diseases in Afghanistan: a realist review.BMC public health · 2025Pooled it
- Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trial.Nature communications · 2024Trial
- Influenza vaccine-specific CD4NPJ vaccines · 2026Article
- Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.Blood advances · 2026Article
- Re-evaluating CD57 as a marker of T cell senescence: implications for immune ageing and differentiation.Immunity & ageing : I & A · 2025Article
- Age-related decline in IgM responses associate with reduced opsonophagocytic activity following PCV13 vaccination.NPJ vaccines · 2025Article
- Incidence of Invasive and Noninvasive Pneumococcal Pneumonia Hospitalizations in People Aged ≥50 Years: Assessing Variability Across Denmark and Spain.The Journal of infectious diseases · 2024Article
- Pre-vaccination immunotypes reveal weak and robust antibody responders to influenza vaccination.Aging cell · 2024Article
- Frailty is related to serum inflammageing markers: results from the VITAL study.Immunity & ageing : I & A · 2023Article
- Article
- Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.EClinicalMedicine · 2023Article
- On the feasibility of using TCR sequencing to follow a vaccination response - lessons learned.Frontiers in immunology · 2023Article
- Synthesis of CuO and PAA-Regulated Silver-Carried CuO Nanosheet Composites and Their Antibacterial Properties.Polymers · 2022Article
- Identification of aging-associated immunotypes and immune stability as indicators of post-vaccination immune activation.Aging cell · 2022Article
- Reply to Anglemyer et al.The Journal of infectious diseases · 2022Article
- Country score tool to assess readiness and guide evidence generation of immunization programs in aging adults in Europe.Frontiers in public health · 2022Review
- Infections and hospital bed-days among aging adults: A five-year retrospective study in a Belgian general hospital.Frontiers in medical technology · 2022Article
- European data sources for computing burden of (potential) vaccine-preventable diseases in ageing adults.BMC infectious diseases · 2021Article
- Antibacterial Cotton Fabric Functionalized with Copper Oxide Nanoparticles.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prevention of infectious diseases through immunisation of the growing ageing adult population is essential to improve healthy ageing. However, many licenced and recommended vaccines for this age group show signs of waning of the protective effect due to declining immune responses (immuno-senescence) and decreasing vaccine uptake. Today's major challenge is to improve vaccine effectiveness and uptake and to deploy efficient vaccination strategies for this age group. The Vaccines and InfecTious diseases in the Ageing popuLation (VITAL) project, with partners from 17 academic & research groups and public institutes as well as seven industry collaborators, aims to address this challenge. The ambition is to provide evidence-based knowledge to local decision makers. Using a holistic and multidisciplinary approach and novel analytical methods, VITAL will provide tools that allow the development of targeted immunisation programs for ageing adults in European countries. The project is based on four pillars focussing on the assessment of the burden of vaccine-preventable diseases in ageing adults, the dissection of the mechanisms underlying immuno-senescence, the analysis of the clinical and economic public health impact of vaccination strategies and the development of educational resources for healthcare professionals. By the end of the project, a clear, detailed, and integrated program should be available for implementing a consistent, affordable, and sustainable vaccination strategy for ageing adults with regular evaluations of its impact over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.